Natural Product (NP) Details
General Information of the NP (ID: NP3710) | |||||
---|---|---|---|---|---|
Name |
Gamma linolenic acid
|
||||
Synonyms |
gamma-Linolenic acid; GAMOLENIC ACID; 506-26-3; (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid; (Z,Z,Z)-6,9,12-Octadecatrienoic acid; (6,9,12)-linolenic acid; CCRIS 7668; all-cis-6,9,12-Octadecatrienoic acid; gamoleic acid; Ligla; UNII-78YC2MAX4O; 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-; GLA; (6Z,9Z,12Z)-Octadecatrienoic acid; Gamma-?Linolenic acid; .gamma.-Linolenic Acid; 6Z,9Z,12Z-octadecatrienoic acid; (6Z,9Z,12Z)-6,9,12-Octadecatrienoic acid; 78YC2MAX4O; cis-Delta(6,9,12)-octadecatrienoic acid; 6(Z),9(Z),12(Z)-Octadecatrienoic acid; 6-cis,9-cis,12-cis-Octadecatrienoic acid; cis,cis,cis-6,9,12-Octadecatrienoic acid; CHEMBL464982; CHEBI:28661; MFCD00065718; 6,9,12-Octadecatrienoic acid; 6,9,12-all-cis-Octadecatrienoic acid; NCGC00160469-01; GAMMA-LINOLENIC ACID (18:3 n-6); C18:3n-6,9,12; cis-6, cis-9, cis-12-octadecatrienoic acid; 18:3 (n-6); Efamast; Epogam; Acido gamolenico; 6Z,9Z,12Z-octadecatrienoate; Acide gamolenique; Acide gamolenique [French]; Acido gamolenico [Spanish]; Acidum gamolenicum; Acidum gamolenicum [Latin]; Gamolenic acid [INN:BAN]; (6Z,9Z,12Z)-Octadecatrienoate; SMR000058609; all-cis-6,9,12-octadecatrienoate; cis-Delta(6,9,12)-octadecatrienoate; Viacutan; Gammolenic acid; gamma-Linolensaeure; Gamma-linoleic acid; gamma-linolenic-acid; gamma-Llnolenic acid; C18:3,n-6; Gamolenic acid (INN); cis-6,cis-9,cis-12-Octadecatrienoic acid; 6,9,12-Octadecatrienoate; DSSTox_CID_26170; DSSTox_RID_81401; DSSTox_GSID_46170; SCHEMBL19418; BSPBio_001338; MLS001333661; MLS001333662; Octadeca-6,9,12-triensaeure; BML3-B06; GTPL4710; DTXSID7046170; NDI 609; HMS1361C20; HMS1791C20; HMS1989C20; HMS2230A18; HMS3402C20; HMS3649H09; 6,9,12-all-cis-Octadecatrienoate; HY-N7140; ZINC3777423; Tox21_111835; BDBM50269532; LMFA01030141; s5743; C18:3, n-6,9,12 all-cis; (Z,Z,Z)-6,9,12-Octadecatrienoate; AKOS022175367; z,z,z-6,9,12-Octadecatrienoic acid; CS-W012291; DB13854; gamma-Linolenic acid, >=99%, liquid; z,z,z-octadeca-6,9,12-trienoic acid; 6(Z),9(Z),12(Z)-Octadecatrienoate; IDI1_033808; gamma-Linolenic acid, analytical standard; NCGC00160469-02; NCGC00160469-03; NCGC00160469-04; C18:3 (n-6); CAS-506-26-3; DS-10685; M520; DB-029858; L0152; Octadecatrienoic acid, 6,9,12-(Z,Z,Z)-; C06426; D07213; 506L263; Q415885; SR-01000838334; SR-01000838334-2; 18:3(N-6); BRD-K18059238-001-02-1; D58CCA4A-7FFA-4E8B-A758-EAA7D073B343; C18H30O2 (cis,cis,cis-octadeca-6,9,12-trienoic acid); UNII-116Z6MZN1M component VZCCETWTMQHEPK-QNEBEIHSSA-N; UNII-44NH37HHP9 component VZCCETWTMQHEPK-QNEBEIHSSA-N; UNII-F85N2YHE4E component VZCCETWTMQHEPK-QNEBEIHSSA-N; cis,cis,cis,6,9,12-Octa-decatrienoic acid-18:3 n6 lithium salt
Click to Show/Hide
|
||||
Species Origin | Gossypium hirsutum ... | Click to Show/Hide | |||
Gossypium hirsutum | |||||
Disease | Allergic/hypersensitivity disorder [ICD-11: 4A80-4A85] | Approved | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C18H30O2
|
||||
PubChem CID | |||||
Canonical SMILES |
CCCCCC=CCC=CCC=CCCCCC(=O)O
|
||||
InChI |
1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-
|
||||
InChIKey |
VZCCETWTMQHEPK-QNEBEIHSSA-N
|
||||
CAS Number |
CAS 506-26-3
|
||||
ChEBI ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
GLA has a synergistic effect with gemcitabine at concentrations that correspond to in vivo therapeutic doses. GLA with 5-FU is synergistic only at a tight range of high concentrations of 5-FU. GLA lacks toxic side effects and may be useful in combination with gemcitabine. | |||||
Vinorelbine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
T-47D | CVCL_0553 | Invasive breast carcinoma | Homo sapiens | |||
SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | |||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Some UFAs can be used as modulators of tumor cell chemosensitivity. |
